Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Status Not yet recruiting

Clinical Trial Summary

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

Clinical Trial Description

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. Azenosertib has been tested as a treatment for other diseases and has shown to stop cancer cell growth. The U.S. Food and Drug Administration (FDA) has not approved Azenosertib as a treatment for recurrent uterine serous carcinoma. This research study involves screening for eligibility, study treatment visits, X-rays, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, Positron Emission Tomography CT (PET-CT) scans, Meta-iodobenzylguanidine (MIBG) scans, Fluorodeoxyglucose Positron Emission Tomography), (FDG-PET) scans, Electrocardiograms (EKGs), tumor biopsies, and blood tests. It is expected that about 25 people will take part in this research study. Zentalis Pharmaceuticals is supporting this research study by providing the study drug Azenosertib. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06369155
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact	Joyce Liu, MD, MPH
Phone	617-632-5269
Email	Joyce_Liu@DFCI.HARVARD.EDU
Status	Not yet recruiting
Phase	Phase 2
Start date	September 2024
Completion date	January 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03285802` - Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation	Phase 2/Phase 3
Completed	`NCT01870947` - Assisted Exercise in Obese Endometrial Cancer Patients	N/A
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Not yet recruiting	`NCT05998811` - Insights Into Participating in Studies for Uterine Cancer
Completed	`NCT01432015` - Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting	Phase 4
Completed	`NCT01399658` - Image-Guided Gynecologic Brachytherapy	Phase 2
Recruiting	`NCT02349958` - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy	Phase 2
Completed	`NCT00581646` - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance	N/A
Completed	`NCT00284427` - Safety of Antioxidants During GYN Cancer Care	Phase 2
Completed	`NCT00147680` - Uterine Papillary Serous Cancer (UPSC) Trial	Phase 2
Recruiting	`NCT05743517` - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)	N/A
Recruiting	`NCT05916196` - [18F]FES PET/.CT in Uterine Cancer	Phase 2
Withdrawn	`NCT04368130` - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care	N/A
Active, not recruiting	`NCT03668340` - AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Phase 2
Completed	`NCT00588640` - Study of D-Methadone in Patients With Chronic Pain	Phase 1/Phase 2
Recruiting	`NCT05990426` - Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy	N/A
Completed	`NCT03701529` - Effect of Anesthetic Agents on Optic Nerve Sheath Diameter	N/A
Recruiting	`NCT05758688` - Whole Pelvis Proton Radiation for Gynecologic Cancer	N/A
Completed	`NCT01953107` - Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.	Phase 4
Completed	`NCT01709175` - Strength Training Study for Survivors of Breast and Gynecologic Cancer	N/A